Simultaneous Resection of Pancreatic Neuroendocrine Tumors with Synchronous Liver Metastases: Safety and Oncological Efficacy

Pietro Addeo 1,*, Caterina Cusumano 1, Bernard Goichot 2, Martina Guerra 3, François Faitot 1, Alessio Imperiale 3,4 and Philippe Bachellier 1

1 Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Pôle des Pathologies Digestives, Hépatiques et de la Transplantation, Hôpital de Hautepierre-Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, 67098 Strasbourg, France; caterina.cusumano@chru-strasbourg.fr (C.C.); martina.guerra@chru-strasbourg.fr (M.G.); francois.faitot@chru-strasbourg.fr (F.F.); philippe.bachellier@chru-strasbourg.fr (P.B.)
2 Internal Medicine, Diabetes and Metabolic Disorders, University Hospitals of Strasbourg, Strasbourg University, 67200 Strasbourg, France; bernard.goichot@chru-strasbourg.fr
3 Nuclear Medicine and Molecular Imaging, Institut de Cancérologie de Strasbourg Europe (ICANS), University Hospitals of Strasbourg, Strasbourg University, 67200 Strasbourg, France; a.imperiale@icans.eu
4 Molecular Imaging—DRHIM, IPHC, UMR 7178, CNRS/Unistra, 67037 Strasbourg, France
* Correspondence: pietrofrancesco.addeo@chru-strasbourg.fr; Tel.: +33-3-8812-7265; Fax: +33-3-8812-7286

Simple Summary: Up to half of all newly diagnosed pancreatic neuroendocrine tumors (PNET) present with liver metastases (LM). The surgical resection of PNETs and LMs can provide complete tumor clearance and improve long-term survival. However, the combination of liver and pancreatic resection simultaneously can theoretically cumulate the morbidity and mortality of two separate operations. In the current study, we analyzed the outcomes of the synchronous surgical resection of PNETs and LMs in 51 patients. There were no differences in the postoperative outcomes in terms of mortality and morbidity according to the type of pancreatic resection. The tumor grade was identified as the sole prognostic factor for survival. The resection of well-differentiated PNETs with LMs was characterized by the longest survival rates (median overall survival 128 months, 5-year overall survival 83%). The optimal sequential surgical strategies for PNETs with LM and the use of neoadjuvant/adjuvant chemotherapy in this category of patients remain to be further investigated.

Abstract: Whether the simultaneous resection of pancreatic neuroendocrine tumors (PNET) with synchronous liver metastases (LM) is safe and oncologically efficacious remains to be debated. We retrospectively reviewed clinical data from patients who underwent the simultaneous resection of PNETs with LMs over the last 25 years. Fifty-one consecutive patients with a median age of 54 years (range 27–80 years) underwent pancreaticoduodenectomy (PD) (n = 16), distal pancreatectomy (DSP) (n = 32) or total pancreatectomy (n = 3) with synchronous LM resection. There were no differences in the postoperative outcomes in terms of mortality and morbidity (p = 0.33) between PD and DSP. The median overall survival (OS) was 64.78 months (95% CI: 49.7–119.8), and the overall survival rates at 1, 3, and 5 years were 97.9%, 86.2% and 61%, respectively. The OS varied according to the tumor grade (G): G1 (OS 128 months, 5-year OS 83%) vs. G2 (OS 60.5 months, 5-year OS 58%) vs. G3 (OS 49.7 months, 5-year OS 0%) (p = 0.03). Multivariate Cox analysis identified G as the only prognostic factor (HR: 5.56; 95% CI: 0.91–9.60; p = 0.01). Simultaneous PNETs with LMs can be performed safely with acceptable morbidity and mortality at tertiary centers. Well-differentiated PNETs had longer survival and might benefit the most from these extended surgeries.

Keywords: neuroendocrine tumors; liver metastases; liver resection; pancreatic resection; survival
1. Introduction

Pancreatic neuroendocrine tumors (PNET) are a rare neoplasm with a biological behavior ranging from indolent to highly aggressive disease. The therapeutic management is based on tumor, disease and patients factors [1,2]. Up to half of all newly diagnosed PNETs present with liver metastases (LM) [3]. The direct venous drainage of the pancreas into the portal system and the tendency of PNETs to spread through tumor thrombosis might explain the high predisposition of PNETs to metastasize to the liver [4].

The treatment of liver metastases of PNET ranges from surgical resection to palliative chemotherapy according to the resectability of the liver metastases. In the presence of resectable disease, usually with less than 50% of the liver volume occupied by LMs, surgery can provide complete tumor clearance and improve long-term survival [1,5]. However, recurrence after the resection of liver PNETs remains expected, but when limited to the liver, it can benefit from repeat local and systemic therapy [3]. Primary PNETs with synchronous resectable liver metastases might pose a surgical challenge, as combining liver and pancreatic resection could add up the morbidity and mortality of two separate potentially highly morbid operations. This could be especially the case for synchronous pancreaticoduodenectomy with major liver resection, which has been characterized by a postoperative mortality rate up to 17% [6]. Several surgical strategies have been reported in presence of synchronous LMS and PNETs, including primary tumor resection and staged liver resection, and the synchronous resection of PNET and LM [7,8]. Because of the rarity of the disease and the need for a combined expertise in liver and pancreatic surgery, series analyzing the outcomes of the synchronous resection of pancreatic PNET with LM remain limited [5,7,9–12]. Herein, we analyze our overall experience in the resection of pancreatic neuroendocrine tumors with synchronous liver metastases, evaluating the safety and oncological efficacy of these combined resections.

2. Materials and Methods

This retrospective cohort study was conducted at the Hepato-Pancreato-Biliary Surgery and Liver Transplantation Center of the University of Strasbourg in France. The study was conducted according to the guidelines of the Declaration of Helsinki. Data were retrospectively analyzed for all of the patients who underwent pancreatic resection for PNET in presence of LM between 1 January 1995 and 31 December 2020. The collected data included demographic, operative (operative time, transfusion requirement, 90-day morbidity and mortality rates), and survival variables. Details were collected on the type of vascular resections (venous and arterial) and the presence and type of the associated visceral resection (colonic, gastric, and intestinal). The preoperative evaluation included thoraco-abdominal computed tomography and/or the magnetic resonance imaging of the abdomen. The functional imaging included OctreoScan In 111 and then PET-Ga 68 when this became available to our institution. Surgical resection was scheduled for patients with good performance status in whom the complete surgical resection of pNET and LMs was judged to be feasible in one-stage or two-stage procedures. The treatment of the LMs included conventional resection and radiofrequency (RF) ablation, and/or a combination of the two. The extent of the pancreatic resection included right resections [(pancreaticoduodenectomy (PD), total pancreatectomy (TP), and distal spleno-pancreatectomy (DSP)]. Major liver resections were defined as the resection of three or more contiguous liver segments. Morbidity was graded according to the Dindo-Clavien classification, with major morbidity including complications classified as IIIA or above [13]. Pancreas-specific complications were defined according to the recommendations from the International Study Group for Pancreatic Surgery, including pancreatic fistula, delayed gastric emptying, and post pancreatectomy hemorrhage [14–16]. PNETs were classified according to the Ki67 index into 3 categories: PNET G1 (<3), PNET G2 (3–20), and PNET G3 (>20) [1]. One expert pathologist reviewed all of the specimens for KI-67 assessment. Follow-up visits were regularly completed in the outpatient clinic and/or with
the referring clinicians. OS was defined as the length of time from the date of surgery to the patient’s death or the last follow-up. The date of the last follow-up was 30 June 2021.

**Statistical Analysis**

The continuous variables are expressed as means ± standard deviations or medians and ranges, as appropriate, and the categorical variables are presented as numbers and percentages. The differences between the groups were assessed by the chi-squared or Fisher’s exact test for categorical variables, as appropriate. In order to compare the continuous variables, the Wilcoxon rank-sum test and Student’s t-test were used, as appropriate. The survival estimates were calculated according to the Kaplan-Meier method, and differences were assessed with the log-rank test. A multivariate analysis was performed using the Cox proportional hazards model. Two-sided p-values were computed, and the level of significance was set at 0.05. Statistical analyses were carried out using the SAS software package (release 9.4, SAS Institute, Cary, NC, USA).

3. Results

**Operative Procedures and Postoperative Outcomes**

During the study period, 51 consecutive patients underwent the synchronous resection of PNETs and liver metastases. The median age was 54 years (range 27–80 years) with a gender ratio of 1.04 (26 men and 25 women) (Table 1).

**Table 1.** Clinical characteristics of the patient population (n = 51).

| Characteristic                                      | Value                        |
|----------------------------------------------------|------------------------------|
| Age                                                | 54 (27–80)                   |
| F/M                                                | 25/26                        |
| Bilairy Stent                                       | 4 (8%)                       |
| Tumor localization                                  |                              |
| Head                                               | 18 (35%)                     |
| Left pancreas                                       | 31 (61%)                     |
| Multifocal                                          | 2 (4%)                       |
| Chromogranine A (µ/L)                               | 150 (19–15,500)              |
| Functional                                          | 6 (11.7%)                    |
| Type of pancreatectomy                              |                              |
| Pancreaticoduodenectomy                             | 16 (31.3%)                   |
| Splenopancreatectomy                                | 32 (63%)                     |
| Total pancreatectomy                                | 3 (6%)                       |
| Operative time                                      | 465 min (180–755)            |
| Venous resection                                    | 16 (31.3%)                   |
| Arterial resection                                  | 3 (6%)                       |
| Liver resection                                     |                              |
| Exclusive resection                                 | 23 (45%)                     |
| Exclusive radiofrequency ablation                   | 7 (13.7%)                    |
| Resection and radiofrequency                        | 21 (41.1%)                   |
| Associated visceral resection                        | 17 (18.4%)                   |
| Transfusions                                        | 14 (27.4%)                   |
| Mortality                                           | 1 (2%)                       |
| Morbidity                                           | 27 (53%)                     |
| Major morbidity                                     | 11 (22%)                     |
| Pancreatic fistula                                  | 9 (17.6%)                    |
| Grade A                                             | 3                            |
| Grade B                                             | 5                            |
| Grade C                                             | 1                            |
| Reoperation                                         | 5 (9.8%)                     |

1 = Data are expressed as the median (range).
Most of the patients had PNET of the left pancreas (61%), while two had multifocal tumors. Functioning PNET with secretory syndrome was present in six patients [Glucagonoma ($n = 2$); Insulinoma ($n = 1$); Gastrinoma ($n = 1$), VIPoma ($n = 2$)]. Seven patients had neoadjuvant treatment including lanreotide ($n = 4$), taxol + bevacizumab ($n = 1$), gemcitabine ($n = 1$), carboplatin-VP16 ($n = 1$). The types of pancreatic resections included PD $n = 16$, DSP $n = 32$ and TP $n = 3$, and the synchronous resection of the mesentericoportal axis was performed in 16 patients, while arterial resection was performed in three. Seventeen patients also had a synchronous visceral resection. Synchronous hepatic resection was performed in 44 patients, while seven had exclusive radiofrequency ablation of LM. In twenty-one patients, resection was combined with RF ablation. Major hepatectomy (two right and two left) was performed synchronously in four patients, and the remaining liver resections were uni-, bi- or trisegmentectomies, and non-anatomical resection. Four patients with bilobar LMs underwent primary tumor resection and the clearance of the future liver remnant as a first stage of two-stage hepatectomy. Two patients failed to undergo the second stage because of postoperative portal vein thrombosis ($n = 1$) and death ($n = 1$). Postoperative mortality was recorded in one patient because of grade C pancreatic fistula eroding visceral vessels. The overall morbidity was 53%, with a major morbidity rate of 22%. Postoperative pancreatic fistula was recorded in 17.6% of the cases. Reoperation was needed in five patients postoperatively in the first 90 postoperative days. The causes of reoperation were hemorrhage due to grade C POPF, in order to derive the splenic vein (SV) after venous resection during PD with SV ligation due to sinistral portal hypertension, abdominal bleeding after DSP, intestinal occlusion, and marginal ulcers in patients with gastrinoma. The pathology showed a median tumor size of 50 mm (range 20–170 mm), with 38 patients having positive lymph nodes, with median numbers of 3 positive lymph nodes (range, 1–25). Most of the patients had G2 tumors (72%), while nine (18%) had G1 tumors and five (9%) had G3 tumors. The median Ki67 tumors were for G1, G2, and G3 of 1.8, 7 and 60, respectively (Table 2).

### Table 2. Pathology ($n = 51$).

| Tumor size (mm) $^1$ | 50 (20–170) |
|----------------------|-------------|
| No lymphnodes involvement (N0) | 13 |
| Lymphnodes invovled (Npos) $^1$ | 3.5 (1–25) |
| Lymphnodes harvested (Ntot) $^1$ | 23 (5–85) |
| Ki-67% $^1$ | 7% (1–80) |
| G1 | 9 (18%) |
| G2 | 37 (72%) |
| G3 | 5 (9%) |

$^1$ = Data are expressed as the median (range).

According to the type of resection, the patients undergoing right pancreatic resection had a statistically significant larger tumor size ($p = 0.03$) and longer operations ($p < 0.00001$), and required more frequent venous resection ($p = 0.04$). There were no differences in the postoperative outcomes in terms of mortality and morbidity or reoperation according to the type of pancreatic resection. No differences were found in terms of the median OS rates between PD and DSP at 67.1 vs. 64.7 months. The median OS was 64.78 months (95% CI: 49.7–119.8, from surgery), and the overall survival rates at 1, 3, 5, and 10 years were 97.9%, 86.2%, 61% and 29% respectively. During the follow-up, 23 patients recurred and 25 died. The median recurrence-free survival duration was 6.68 months (95% CI: 4.2–11.2). The median overall survival was longer in patients aged less than 65 years (67.0 months vs. 49.0 months; $p = 0.08$) and for G1 tumors (median OS 128 months, 5-year OS 83%) vs. G2 tumors (median OS 60.5 months, 5-year OS 58%) vs. G3 (median OS 49.7 months, 5-year OS 0%) ($p = 0.03$) (Figure 1).
Multivariate Cox analysis identified G3 tumours as the only prognostic factors (HR: 5.56; 95% CI: 0.91–9.60; p = 0.01) (Table 3).

Table 3. Univariate and multivariate Cox regression analysis of the overall survival in relation to the clinicopathologic features.

| Characteristics          | Median Survival Log-Rank (Months) | Univariate Analysis | Multivariate Analysis |
|--------------------------|----------------------------------|---------------------|-----------------------|
| Age (years)              |                                  |                     |                       |
| <65 vs. 65 years         | 67.0                             | 2.37 (0.89–6.25)    | 0.08                  |
| Jaundice                 |                                  |                     |                       |
| Yes                      | 41.0                             | 1.96 (0.64–5.86)    | 0.23                  |
| Not                      | 64.0                             |                     |                       |
| Functional tumors        |                                  |                     |                       |
| Yes                      | 64.0                             | 0.84 (0.24–2.86)    | 0.78                  |
| Not                      | 64.7                             |                     |                       |
| Tumor site               |                                  |                     |                       |
| Right                    | 67.1                             | 0.59 (0.25–1.42)    | 0.24                  |
| Left                     | 64.1                             |                     |                       |
| Type of pancreatectomy   |                                  |                     |                       |
| PD                       | 67.1                             | 0.69 (0.24–1.52)    | 0.28                  |
| DSP                      | 64.7                             | 5.26 (0.91–30.4)    | 0.06                  |
| TP                       | 35.2                             |                     |                       |
| Venous Resection         |                                  |                     |                       |
| Yes                      | 67.1                             | 0.76 (0.27–2.17)    | 0.60                  |
| No                       | 64.7                             |                     |                       |
| Number of LM             |                                  |                     |                       |
| 2                        | 128.8                            | 2.25 (0.65–7.74)    | 0.19                  |
| >2                       | 64.0                             |                     |                       |
| Radiofrequency ablation  |                                  |                     |                       |
| Yes                      | 60.5                             | 0.67 (0.48–1.34)    | 0.40                  |
| Not                      | 119.6                            |                     |                       |
4. Discussion

This study demonstrated that, in a specialized setting, the synchronous resection of PNETs with liver metastases can be performed with mortality and morbidity comparable to standard pancreatic resection. The oncological efficacy of this aggressive approach was associated with prolonged survival, especially in the presence of well-differentiated PNETs such as those reported in previous series [7,9,12]. The tumors’ grade differentiation, rather than the type of pancreatic resection and/or the localization of liver metastases, influences the oncologic outcomes.

Combining liver and pancreatic resection carries the risk of cumulating the specific morbidities of the two separate operations. Cumulating the effect of a pancreatic and biliary fistula with liver failure can bring a mortality rate of up to 17%, as was demonstrated by a recent multicentric study on hepatopancreaticoduodenectomy [6]. In addition, because PNETs are most commonly discovered incidentally, patients present with soft pancreas and a not dilated pancreatic duct, which carries a higher risk of pancreatic fistulas. In fact, in the current study only four patients presented with jaundice and received a preoperative biliary stent. In the group of patients undergoing PD, the rate of postoperative clinically significant pancreatic fistula was 18% (3/16), with one postoperative death due to late bleeding. This patient—who received left-liver clearance and PD as a part of a two-stage procedure—had no biliary fistulas, but only POPF, which was the source of the lethal bleeding. This mortality arrived despite our policy of not combining major liver resection with PD. Kianmanesh et al. [8]—who reported a large series of two-stage procedures to treat primary NETs and LMs—reported no death, but only used this strategy in patients with left pancreatic tumors. Because of the expected long-term survival of well-differentiated metastatic PNETs, we believe that in patients with bilobar LMs and PNETs of the pancreatic head, synchronous resection should cautiously be planned. One strategy could be to separate the planned procedure into three stages, with primary tumor resection being performed as a last step in the presence of non-symptomatic PNET of the head, or a first step in the case of symptomatic tumors (jaundice, digestive symptoms, or venous contact). Postponing primary tumor resection could give priority to LMs which conditioned the overall survival of those patients while minimizing the risk of cumulating morbidities. Five patients required reoperation in this experience at a similar rate between left and right pancreatic resection. Only two were related to specific pancreatic complications, a rate which is in the range of that reported for pancreatic resections.

The role of neoadjuvant chemotherapy in patients with LMs from PNETs remains to be evaluated [17]. Preoperative neoadjuvant chemotherapy has not been associated with tumor downstaging in locally advanced PNETs [18], but it seems to improve the results of the resection of LMs from PNETs. Cloyd et al. [19] reported that the use of Fluorouracil, Doxorubicin, and Streptozocin (FAS) was associated with improved overall and disease-free survival when used in neoadjuvant settings in patients with LM from PNETs, com-
pared with upfront resection. The use of neoadjuvant FAS in patients undergoing the syn-
chronous resection of PNET with LMs (n = 46) was associated with improved median OS
[97.3 months (95% CI 65.9–128.6) vs. 65.0 months (95% CI 28.1–101.9), p = 0.001] and RFS
[24.8 months (95% CI 22.6–26.9) vs. 12.1 months (2.2–22.0), p = 0.003] compared to upfront
resections. In our study, we did not have experience with this type of treatment because,
in France, surgery is considered first in the presence of resectable liver disease. A prospec-
tive randomized study could be helpful to define the use of neoadjuvant FAS in the pres-
ence of PNETS with LMs, because the results of this treatment appear promising [19]. A
weighted balance between safety and oncologic efficacy should guide surgeons when con-
sidering the combination of liver and pancreatic resection for metastatic PNETs. Liver re-
section for LMs of PNET has been associated with improved disease-specific survival
when compared with unresected LMs. Klein et al. [9] reported that, among patients with
LMs, the mortality rate was higher in those in whom liver resection was not possible than
in patients who had liver resection (HR 9= 24.1–85.18; p = 0.049). In addition, patients who
had liver resection had similar disease-specific survival to those without liver metastases
(HR 0.84, 0.09 to 7.57; p = 0.877), and the tumor grade strongly influenced the overall sur-
vival. This study, however, presented a noteworthy selection bias.

In the current study, we confirmed that in PNET tumor grade differentiation was a
prognostic factor for the overall survival in presence of LMs [1,11,20]. Neither the tumor
localization nor the extent of liver disease (even when resectable) had a greater impact
than the tumor grade differentiation on the overall disease-specific survival. Well-differ-
entiated PNETs showed longer survival rates (median OS 128 months, 5-year OS 83%),
underlining the oncological efficacy in this patient population and the need to carefully
evaluate the risk of surgical procedures in this population (Figure 2).

![Figure 2](image-url)

**Figure 2.** Two clinical cases of PNET of the left pancreas with bilobar LM treated by synchronous
resection. Panel (A–C): a 54-year-old patient with well-differentiated PNET of the left pancreas
(KI-67 2%) with bilobar LMs who underwent left splenopancreatectomy with right hepatectomy
and the tumorectomy of segment 2. The patient is alive without recurrence at 9 years. Panel (D–F):
a 50-year-old patient with moderately differentiated PNET (KI-67 3%) tumoral thrombosis of the
splenic and portal vein thrombosis (blue arrow), and bilobar LMS. The patient underwent simulta-
neous left splenopancreatectomy with right hepatectomy and portal thrombectomy. Multiple
liver resection and the RF ablation of LM into the left liver were performed three months later as a
second step of a two-stage strategy. The patient is alive with liver recurrence under medical treat-
ment 6 years later.
The biology of the tumor should cautiously guide surgeons in the planning of aggressive surgery with potential morbidity, especially when scheduling PD for well-differentiated tumors of the pancreatic head in the presence of LMs. In this high-risk situation with soft pancreas and/or obese patients, separating the entire sequence in multiple separate stages could be an option. Additionally, these patients should be referred to tertiary centers for the minimization of postoperative morbidity.

Even if the results presented in the current study appeared favourable in terms of postoperative morbidity, the role of these extensive surgeries for PNETs in the presence of LMs remains to be debated, especially in the case of the PNET of the pancreatic head. The surgical resection of PNET of the left pancreas in the presence of non-resectable LMs seems to be associated with improved survival compared with non-operated patients [21]. While this seems to be related mostly to a selection bias, the surgical resection of the primary could be associated with fewer local complications, and could decrease the tumoral burden while leaving only liver disease to be treated either locally or by systemic therapy. While liver resection should be performed in the presence of diffuse, liver involvement also remains to be discussed. Recent advances in interventional radiology procedures including chemo and radioembolization seems to improve local control [1–3]. The benefit of liver resection should always to be balanced against the inherent risk of surgery.

This study presents several limitations that deserve comments. First, its small size and the retrospective nature come with inherent limitations. A multicentric study exploring the policies and resection strategies of referral centres for PNETs with LMs could provide a further body of literature on this point. Second, the role of neoadjuvant and adjuvant treatment in this patient population with a high tumoral burden remain to be explored. It is likely that the use of neoadjuvant treatment could select the ideal patient population for these aggressive surgeries. Third, the optimal therapeutic sequence for the treatment of the primary PNET and LMs remains to be determined. Again, a multicentric study could help to identify the optimal treatment strategy for patients with PNET and LM. Fourth, we could not capture the exact denominator of this study regarding the patients that were seen at our institution and were judged not to be resectable. Finally, this study lacked a comparative analysis with other non-surgical treatment for LM, or a comparison with an exclusive control group treated by medical treatment.

5. Conclusions

Simultaneous liver resection for metastatic pancreatic neuroendocrine tumors (PNET) can be performed safely with acceptable morbidity and mortality at tertiary centers. Well-differentiated PNETs showed longer survival, and might benefit the most from these extended surgeries. Optimal sequential surgical strategies for PNETs with LM and the use of neoadjuvant and adjuvant chemotherapy in this context remain to be further evaluated.

Author Contributions: Conceptualization, P.A., A.I. and P.B.; methodology, P.A., C.C., B.G., M.G., P.B., A.I. and F.F.; formal analysis, P.A., C.C., B.G., M.G., F.F., P.B. and A.I.; investigation, P.A., C.C., B.G., M.G., F.F., P.B. and A.I.; resources, A.I.; writing—original draft preparation, P.A.; writing—review and editing, P.A.; visualization, P.A., C.C., B.G., M.G., F.F., P.B. and A.I.; supervision, P.A., C.C., B.G., M.G., P.B., F.F. and A.I.; project administration, P.A., C.C., B.G., M.G., F.F., P.B. and A.I. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and has been approved by Medical school, dental school, pharmaceutical school, nursing school, physiotherapy school, medical school and hospital ethic committee on 13 January 2022 (ethic code: CE-2022-2).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.
Data Availability Statement: The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Cloyd, J.M.; Poultsides, G.A. The Landmark Series: Pancreatic Neuroendocrine Tumors. Ann. Surg. Oncol. 2021, 28, 1039–1049. https://doi.org/10.1245/s10434-020-09133-x.

2. Megdanova-Chipeva, V.G.; Lamarca, A.; Backen, A.; McNamara, M.G.; Barriuso, J.; Sergieva, S.; Gocheva, L.; Mansoor, W.; Manoharan, P.; Valle, J.W. Systematic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs). Cancers 2020, 12, 1988. https://doi.org/10.3390/cancers12071988.

3. Grandhi, M.S.; Lafaro, K.J.; Pawlik, T.M. Role of Locoregional and Systemic Approaches for the Treatment of Patients with Metastatic Neuroendocrine Tumors. J. Gastrointest. Surg. 2015, 19, 2273–2282. https://doi.org/10.1007/s11605-015-2931-z.

4. Addeo, P.; d’Alessandro, A.; Averous, G.; Imperiale, A.; Taitot, F.; Goichot, B.; Bachellier, P. Macrovascular venous invasion of pancreatic neuroendocrine tumours: Impact on surgical outcomes and survival. HPB 2019, 21, 653–661. https://doi.org/10.1016/j.hpb.2018.10.010.

5. Bruzoni, M.; Parikh, P.; Celis, R.; Are, C.; Ly, Q.P.; Meza, J.L.; Sasson, A.R. Management of the primary tumor in patients with metastatic pancreatic neuroendocrine tumor: A contemporary single-institution review. Ann. J. Surg. 2009, 197, 376–381. https://doi.org/10.1016/j.amjsurg.2008.11.005.

6. D’Souza, M.A.; Valdimarsson, V.T.; Campagnaro, T.; Cauchy, F.; Chatzizacharias, N.A.; D’Hondt, M.; Dasari, B.; Ferrero, A.; Franken, L.C.; Fusai, G.; et al. Hepatopancreatoduodenectomy: a controversial treatment for bile duct and gallbladder cancer from a European perspective. HPB 2020, 22, 1339–1348. https://doi.org/10.1016/j.hpb.2019.12.008.

7. Gaujoux, S.; Gonen, M.; Tang, L.; Klimstra, D.; Brennan, M.F.; D’Angelica, M.; Dematteo, R.; Allen, P.J.; Jarnagin, W.; Fong, Y. Synchronous resection of primary and liver metastases for neuroendocrine tumors. Ann. Surg. Oncol. 2012, 19, 4270–4277. https://doi.org/10.1245/s10434-012-2462-8.

8. Kianmanesh, R.; Sauvanet, A.; Hentic, O.; Couvelard, A.; Levy, P.; Vilgrain, V.; Ruszniewski, P.; Belghiti, J. Two-step surgery for synchronous bilobar liver metastases from digestive endocrine tumors: A safe approach for radical resection. Ann. Surg. 2008, 247, 659–665. https://doi.org/10.1097/SLA.0b013e31816a7061.

9. Kleine, M.; Schrem, H.; Vondrach, F.W.; Krech, T.; Klemm, J.; Bektas, H. Extended surgery for advanced pancreatic endocrine tumours. Br. J. Surg. 2012, 99, 88–94. https://doi.org/10.1002/bjs.7681.

10. Heidenreich, B.M.; Kemp Bohan, P.M.; Flor, J.R.; Bader, J.O.; Vreeland, T.J.; O’Connor, V.V.; Nelson, D.W. Examining Perioperative Risk Associated with Simultaneous Resection of Primary Neuroendocrine Tumors and Synchronous Hepatic Metastases. World J. Surg. 2021, 45, 531–542. https://doi.org/10.1007/s00268-020-05847-x.

11. Birnbaum, D.J.; Turri, O.; Viganò, L.; Russollillo, N.; Autret, A.; Moutardier, V.; Capussotti, L.; Le Treut, Y.P.; Delpero, J.R.; Hardwigsen, J. Surgical management of advanced pancreatic neuroendocrine tumors: Short-term and long-term results from an international multi-institutional study. Ann. Surg. Oncol. 2015, 22, 1000–1007. https://doi.org/10.1245/s10434-014-0416-8.

12. Schurr, P.G.; Strate, T.; Ress, K.; Kaifer, J.T.; Reichelt, U.; Petri, S.; Kleinhaus, H.; Yekebas, E.F.; Izibicki, J.R. Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: An institutional experience. Ann. Surg. 2007, 245, 273–281. https://doi.org/10.1097/01.sla.00003022556.24258.68.

13. Dindo, D.; Demartines, N.; Clavien, P.A. Classification of surgical complications: A new proposal with evaluation in a cohort of 6356 patients and results of a survey. Ann. Surg. 2004, 240, 205–213. https://doi.org/10.1097/01.sla.0000133083.54934.ac.

14. Bassi, C.; Marchegiani, G.; Dervenis, C.; Sarr, M.; Abu Hilal, M.; Adham, M.; Allen, P.; Andersson, R.; Ashburn, H.J.; Besselink, M.G.; et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery 2017, 161, 584–591. https://doi.org/10.1016/j.surg.2016.11.014.

15. Wente, M.N.; Bassi, C.; Dervenis, C.; Fingerhut, A.; Gouma, D.J.; Izibicki, J.R.; Neoptolemos, J.P.; Padbury, R.T.; Sarr, M.G.; Traverso, L.W.; et al. Delayed gastric emptying (DGE) after pancreatic surgery: A suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 2007, 142, 761–768. https://doi.org/10.1016/j.surg.2007.05.005.

16. Wente, M.N.; Veit, J.A.; Bassi, C.; Dervenis, C.; Fingerhut, A.; Gouma, D.J.; Izibicki, J.R.; Neoptolemos, J.P.; Padbury, R.T.; Sarr, M.G.; et al. Postpancreatectomy hemorrhage (PPH): An International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery 2007, 142, 20–25. https://doi.org/10.1016/j.surg.2007.02.001.

17. Ricci, C.; Partelli, S.; Landoni, L.; Rinzivillo, M.; Ingaldì, C.; Andreasi, V.; Nessi, C.; Muffatti, F.; Fontana, M.; Tamburrino, D.; et al. Sporadic non-functioning pancreatic neuroendocrine tumors: Multicentre analysis. Br. J. Surg. 2021, 108, 811–816. https://doi.org/10.1093/bjs/znz411.

18. Prakash, L.; Bhosale, P.; Cloyd, J.; Kim, M.; Parker, N.; Yao, J.; Dasari, A.; Halperin, D.; Aloia, T.; Lee, J.E.; et al. Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors. J. Gastrointest. Surg. 2017, 21, 155–163. https://doi.org/10.1007/s11605-016-3270-4.

19. Cloyd, J.M.; Omichi, K.; Mizuno, T.; Kawaguchi, Y.; Tzeng, C.D.; Conrad, C.; Chun, Y.S.; Aloia, T.A.; Katz, M.H.G.; Lee, J.E.; et al. Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver Metastases. Ann. Surg. Oncol. 2018, 25, 1709–1715. https://doi.org/10.1245/s10434-018-6468-8.
20. Zaidi, M.Y.; Lopez-Aguiar, A.G.; Switchenko, J.M.; Lipscomb, J.; Andreasi, V.; Partelli, S.; Gamboa, A.C.; Lee, R.M.; Poultsides, G.A.; Dillhoff, M.; et al. A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors: An International Study of 1006 Patients. *Ann. Surg.* **2019**, *270*, 422–433. https://doi.org/10.1097/SLA.0000000000003461.

21. Bertani, E.; Fazio, N.; Radice, D.; Zardini, C.; Spinoglio, G.; Chiappa, A.; Ribero, D.; Biffi, R.; Partelli, S.; Falconi, M. Assessing the role of primary tumour resection in patients with synchronous unresectable liver metastases from pancreatic neuroendocrine tumour of the body and tail. A propensity score survival evaluation. *Eur. J. Surg. Oncol.* **2017**, *43*, 372–379. https://doi.org/10.1016/j.ejso.2016.09.011.